Conversely, CCR2 shRNA knockdown or ablation by CRISPR knockout in DCIS.com breast cancer cells inhibits the number of invasive lesions, limiting DCIS progression18. The gene discussed is CCR2; the disease is ductal breast carcinoma in situ.